The Journal of Allergy and Clinical Immunology
Volume 119, Issue 6 , Pages 1454-1461 , June 2007

Real-world Evaluation of Asthma Control and Treatment (REACT): Findings from a national Web-based survey

  • Stephen P. Peters, MD, PhD

      Affiliations

    • From the Center for Human Genomics and the Department of Internal Medicine, Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University School of Medicine, Winston-Salem
    • Corresponding Author InformationReprint requests: Stephen P. Peters, MD, PhD, Center for Human Genomics and Department of Internal Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157.
    • ,
  • Craig A. Jones, MD

      Affiliations

    • Division of Allergy and Immunology, Department of Pediatrics, Los Angeles County and University of Southern California Medical Center, Los Angeles
    • ,
  • Tmirah Haselkorn, PhD

      Affiliations

    • Genentech, Inc., South San Francisco
    • ,
  • David R. Mink, MS

      Affiliations

    • Ovation Research Group, San Francisco
    • ,
  • David J. Valacer, MD

      Affiliations

    • Genentech, Inc., South San Francisco
    • ,
  • Scott T. Weiss, MD

      Affiliations

    • Channing Laboratory, Center for Genetics and Genomics, Brigham & Women's Hospital, Harvard Medical School, Boston

Received 1 September 2006 ,Revised 20 March 2007 ,Accepted 22 March 2007.

  • Image Result

    Treating physician for patients with controlled asthma and uncontrolled asthma. There were no statistically significant differences in treating specialty between the controlled and uncontrolled groups

    Treating physician for patients with controlled asthma and uncontrolled asthma. There were no statistically significant differences in treating specialty between the controlled and uncontrolled groups.

  • Image Result
    Asthma medication regimens for patients with controlled asthma (n = 809) and patients with uncontrolled asthma (n = 1003). The medication regimens most commonly used in each group were similar; the ma

    Asthma medication regimens for patients with controlled asthma (n = 809) and patients with uncontrolled asthma (n = 1003). The medication regimens most commonly used in each group were similar; the majority of patients were taking an inhaled corticosteroid (ICS) and long-acting β-agonist (LABA). Approximately twice as many patients with uncontrolled asthma were taking an oral steroid (OS) alone or in combination with another medication (P < .0001). LTRA, Leukotriene modifiers.

 Supported by Genentech, Inc, South San Francisco, Calif.Disclosure of potential conflict of interest: S. P. Peters has consulting arrangements with and is on the speakers' bureau for Genentech and Novartis. C. A. Jones has consulting arrangements with Genentech, Merck, Sanofi-Aventis, and AstraZeneca; has received grant support from Genentech and Merck; and is on the speakers' bureau for Genentech, Merck, Sanofi-Aventis, and AstraZeneca. T. Haselkorn has consulting arrangements with Genentech. D. R. Mink is employed by Ovation Research Group, which receives grant support from Genentech. D. J. Valacer owns stock in Genentech and General Electric and is employed by Genentech. S. T. Weiss has consulting arrangements with Glaxo-Wellcome, Roche Pharmaceuticals, Millennium Pharmaceuticals, Genentech, Schering-Plough, Variageics, Genome Therapeutics, and Merck Frost and has received grant support from Glaxo-Wellcome, AstraZeneca, and Pfizer.

PII: S0091-6749(07)00619-7

doi: 10.1016/j.jaci.2007.03.022

The Journal of Allergy and Clinical Immunology
Volume 119, Issue 6 , Pages 1454-1461 , June 2007

Article Tools

* Image Usage & Resolution